Related Experiment Video
Updated: Jul 20, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
[Pharmacological properties and its significance in clinical practice]
1Development Research Laboratories, Banyu Pharmaceutical Co. Ltd.
Insights
Losartan, an angiotensin II (AngII) type 1 (AT1) receptor antagonist, offers benefits beyond hypertension treatment. It may reduce mortality in heart failure patients and lower uric acid levels by inhibiting kidney reabsorption.
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Context:
- Losartan is the first orally active angiotensin II (AngII) type 1 (AT1) receptor antagonist for hypertension.
- It has demonstrated potential mortality reduction in heart failure patients compared to captopril.
- Emerging research indicates losartan's effects on uric acid metabolism and thromboxane A2 (TXA2) receptors.
Purpose:
- To explore the multifaceted pharmacological actions of losartan.
- To investigate losartan's impact on serum uric acid levels and its mechanism of action.
- To assess losartan's affinity for thromboxane A2 (TXA2) receptors.
Summary:
- Losartan selectively blocks the angiotensin II (AngII) type 1 (AT1) receptor.
- It reduces serum uric acid by inhibiting proximal tubule reabsorption in the kidney.
- Losartan exhibits competitive inhibition of thromboxane A2 (TXA2) receptors in platelets and vascular smooth muscle.
Impact:
- Losartan's efficacy extends beyond AT1 receptor blockade, potentially benefiting hypertensive patients with elevated uric acid or cardiovascular risks.
- The drug's dual action on uric acid and TXA2 receptors may offer additional cardiovascular protection.
- Losartan represents a significant advancement in managing hypertension and related cardiovascular comorbidities.
Abstract:
Losartan is a potent non-peptide, selective angiotensin II (AngII) type 1 (AT1) receptor antagonist. Losartan has been worldwide marketed as the first orally active AT1 receptor antagonist with once-daily dosing for treatment of hypertension. In a study of patients with heart failure, the mortality appeared to be lower with losartan than with the ACE inhibitor captopril. In healthy subjects, losartan produced a dose-dependent reduction in serum uric acid. The mechanism of action is considered to be the inhibition of reabsorption of uric acid in the proximal tubules of the kidney. Furthermore, it was recently reported that losartan has moderate affinity for the thromboxane (TX) A2 receptor in a competitive-inhibition manner in the platelets and vascular smooth muscle. The efficacy of losartan with regard to not only AT1 receptor blockade, but also the reduction of serum uric acid and the blockade of TXA2 receptors, may be advantageous to patients with hypertension having these cardiovascular risk factors.
More Related Videos
Related Concept Videos
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Dose-Response Relationship: Selectivity and Specificity
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Tissue-Drug Binding: Localization of Drugs and its Significance
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...
Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic Responses: Different Types

